Core Viewpoint - RenovoRx, Inc. is advancing its TAMP therapy platform for treating locally advanced pancreatic cancer (LAPC) and will present clinical data at the Symposium on Clinical Interventional Oncology [1][3] Company Overview - RenovoRx is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies using a local drug delivery platform aimed at improving therapeutic outcomes for cancer patients [7] - The company's TAMP (Trans-Arterial Micro-Perfusion) therapy platform is designed to deliver chemotherapy directly to tumors while minimizing systemic side effects [7][8] Clinical Trials and Research - The ongoing Phase III TIGeR-PaC clinical trial is evaluating the TAMP therapy platform in combination with gemcitabine HCl for LAPC patients [4][6] - The first interim analysis of the TIGeR-PaC trial was completed in March 2023, with recommendations to continue the study [6] - The primary endpoint of the trial is a 6-month Overall Survival benefit, with secondary endpoints focusing on reduced side effects compared to standard care [6] Presentation Details - Dr. Ripal Gandhi will present on September 21, 2024, discussing the clinical challenges of standard care for LAPC and the potential of TAMP therapy as a targeted treatment option [5][3] - The presentation will also cover recent publications of clinical data related to the TAMP platform and its application in LAPC [4][3]

Core Viewpoint - RenovoRx, Inc. is set to present at H.C. Wainwright's 26th Annual Global Investment Conference, highlighting its advancements in precision oncology therapies and ongoing clinical trials for pancreatic cancer treatment [1][2]. Company Overview - RenovoRx is a clinical-stage biopharmaceutical company focused on developing novel precision oncology therapies using a local drug-delivery platform aimed at improving therapeutic outcomes for cancer patients [7]. - The company's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to deliver chemotherapy directly to tumors while minimizing systemic toxicity [7][8]. Clinical Trials - The ongoing Phase III TIGeR-PaC clinical trial is evaluating the TAMP™ therapy platform for treating Locally Advanced Pancreatic Cancer (LAPC) [5][6]. - The primary endpoint of the trial is a 6-month Overall Survival benefit, with secondary endpoints including reduced side effects compared to standard care [6]. - The first interim analysis was completed in March 2023, with a recommendation to continue the study, and the second interim analysis is expected in late 2024 or early 2025 [6]. Recent Developments - Shaun Bagai, CEO of RenovoRx, will discuss recent corporate achievements and the exploration of new commercial business development opportunities at the upcoming conference [2][3]. - The company appointed Ryan Witt as Senior Vice President of Corporate Strategy and Partnerships in June 2024 to enhance its business development efforts [2]. Product Information - RenovoRx's first product candidate utilizing the TAMP technology involves the intra-arterial administration of gemcitabine HCl via the FDA-cleared RenovoCath® device [5][7]. - RenovoCath is indicated for temporary vessel occlusion in various applications, including arteriography and chemotherapeutic drug infusion [2][7].

Core Viewpoint - RenovoRx is advancing its Phase III clinical trial, TIGeR-PaC, for RenovoGem™ aimed at treating Locally Advanced Pancreatic Cancer (LAPC), with the first patient enrolled at the University of Nebraska Medical Center [1][3]. Company Overview - RenovoRx is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies using a local drug delivery platform [8]. - The company’s lead product candidate, RenovoGem™, is a drug-device combination utilizing the FDA-cleared RenovoCath® device for intra-arterial chemotherapy delivery [5][8]. Clinical Trial Details - The TIGeR-PaC study employs the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform to deliver gemcitabine directly to the tumor site, potentially overcoming barriers posed by scar tissue around pancreatic tumors [2][3]. - The trial is designed as a randomized multi-center study, with primary endpoints focused on 6-month Overall Survival benefits and secondary endpoints assessing reduced side effects compared to standard intravenous chemotherapy [6][5]. Enrollment and Collaboration - Enrollment for the TIGeR-PaC trial began in June 2024, with UNMC being the latest site to participate, expected to enhance patient recruitment due to its high volume of pancreatic cancer cases [1][4]. - The collaboration with UNMC aims to improve patient outcomes and advance the study towards completion [3][4]. Market Context - Pancreatic cancer is characterized by a low 5-year survival rate of 13% across all stages, with LAPC being particularly challenging as it is diagnosed when the cancer cannot be surgically removed [7]. - The ongoing research and development efforts by RenovoRx are positioned to address significant unmet medical needs in the treatment of LAPC [9].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ | --- | --- | |----------------------------------------------------------------------------------------------------------------------|---- ...

Targeted chemotherapy delivery via TAMP is currently being evaluated in an ongoing Phase III clinical trial in LAPC "These important foundational studies highlight the potential for a meaningful advancement in the standard of care for cancer treatment, with less toxicity and improved outcomes," said Hassan Hatoum, MD. "These clinical data support that TAMP has the potential to extend OS compared to systemic chemotherapy in difficult-to-treat solid tumors and provide a paradigm-shifting treatment option for ...

LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced acceptance for publication in an international peer-reviewed journal, The Oncologist. The manuscript is titled, "Treatment of Locally Advanced Pancreatic Cancer (LAPC) Using Localized Trans-Arterial Micro Perfusion (TAMP™) of Gemcitabine: Combined Anal ...

Ramtin Agah, Chief Medical Officer and Founder of RenovoRx states, "These important studies investigate clinical outcomes along with procedural variables that may impact those clinical outcomes." The Oncologist is an international peer-reviewed Journal for the practicing oncologists and hematologists. It is dedicated to translating the latest research developments into the best multidimensional care for cancer patients and is committed to helping physicians excel in this ever-expanding environment through t ...

LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company's ongoing pivotal Phase III TIGeR-PaC clinical trial. The TIGeR-PaC study is using RenovoRx's patented TAMP (Tr ...

The TIGeR-PaC study is using RenovoRx's patented TAMP (Trans-Arterial Micro-Perfusion) therapy platform to evaluate its RenovoGem investigational drug-device combination product. RenovoGem utilizes pressuremediated delivery of chemotherapy across the arterial wall to bathe tumor tissue. The study is comparing treatment with TAMP to the current standard-of-care (systemic intravenous chemotherapy). "We are proud to partner with Dr. Klute and her team in our Phase III TIGeR-PaC trial," said Leesa Gentry, Chief ...

Company Overview - RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform aimed at improving therapeutic outcomes for cancer patients [4] - The company's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target tumors while potentially minimizing toxicities compared to systemic intravenous therapy [4] - RenovoRx's lead product candidate, RenovoGem™, is a novel oncology drug-device combination product currently in Phase III clinical development for the treatment of locally advanced pancreatic cancer (LPAC) [4][5] Leadership and Strategy - Ryan Witt has been appointed as Senior Vice President, Head of Corporate Strategy and Partnerships, bringing extensive corporate strategy and operational experience from roles at Spinogenix, Immix Biopharma, StartX, and UCLA Biodesign [1][7][9] - Mr Witt's leadership will focus on advancing RenovoRx's pivotal Phase III clinical trial, expanding development opportunities into additional cancers, and exploring new commercial business development opportunities with the company's therapeutic technology [9] - The appointment highlights RenovoRx's commitment to exploring and executing on clinical and commercial business development opportunities for its RenovoGem™ investigational combination product and other therapeutic agents [5] Technology and Pipeline - RenovoRx's TAMP™ therapy platform offers the potential for increased safety, tolerance, and improved efficacy in targeted cancer treatment [4] - RenovoGem™ is being investigated under a US investigational new drug application regulated by the FDA's 21 CFR 312 pathway for the treatment of LPAC [4] - The company is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care [6] Industry and Partnerships - Mr Witt has a strong track record in leading corporate strategy and managing partnerships across top 25 global biopharma companies [1] - He serves on Biocom's Capital Development Committee, which hosts Partnering Days with large multinational healthcare companies including Baxter, Bristol Myers Squibb, Daiichi-Sankyo, GSK, Novo Nordisk, and Eli Lilly [1] - RenovoRx has collaborated with Imugene and has clinical data delivering gemcitabine with its drug-delivery platform, demonstrating the potential of its technology [4]